Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
04:05pm, Tuesday, 15'th Apr 2025
Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
11:50am, Monday, 14'th Apr 2025
STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 re
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Thera
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Thera
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
07:00am, Friday, 27'th Dec 2024
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common
Alessia's fans will experience a behind-the-scenes look at the creative process for her Love & Hyperbole album trailer through an episodic series, brought to life by Lenovo's smarter technology and In
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA
12:52pm, Wednesday, 18'th Dec 2024
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securit
Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
07:56am, Wednesday, 18'th Dec 2024
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi. Click here to learn how t
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
07:00am, Wednesday, 18'th Dec 2024
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
12:21pm, Thursday, 13'th Jun 2024
Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Why Is Cara Therapeutics (CARA) Stock Down 27% Today?
08:44am, Thursday, 13'th Jun 2024
Cara Therapeutics (NASDAQ: CARA ) stock is falling hard on Thursday after the development-stage biopharmaceutical company announced new data from a clinical trial. This data comes from the company's
Cara Therapeutics discontinues study on a neurological condition as drug fails
04:19pm, Wednesday, 12'th Jun 2024
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
04:01pm, Wednesday, 12'th Jun 2024
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
06:11pm, Monday, 13'th May 2024
Cara Therapeutics (CARA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.49 per share a year ago.
Cara Therapeutics Reports First Quarter 2024 Financial Results
04:01pm, Monday, 13'th May 2024
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 Topline efficacy and safety results from KOURAGE 1 Part
